Federated Hermes
LYRA

Federated Hermes’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Federated Hermes’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-600
Closed -$335K – 2284
2020
Q3 		$335K Hold
600
– – ﹤0.01% 1573
2020
Q2 		$340K Buy
+600
New +$439K ﹤0.01% 1555

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Federated Hermes's LYRA Position: Q4 2020 in Review

Federated Hermes sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2020, closing a stake of 600 shares — an estimated $335K sold.

Federated Hermes first reported a position in LYRA in Q2 2020 and held it in 2 quarters. The position peaked at $340K in Q2 2020. 43 funds tracked by Wall St. Rank hold LYRA as of Q4 2020.

  • Federated Hermes reported no remaining LYRA THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Federated Hermes sold 600 LYRA THERAPEUTICS INC shares in Q4 2020, an estimated $335K.
  • Federated Hermes first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 2 quarters.
  • Federated Hermes's LYRA THERAPEUTICS INC position peaked at $340K in Q2 2020.
  • 43 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2020.

Based on Federated Hermes's 13F filing for Q4 2020, filed 12 Feb 2021.